AI-generated summary
This brief review describes low-level laser therapy, also called photobiomodulation, as applied to depression, and discusses possible mechanisms and limitations. The authors report that preclinical animal studies show neuroprotective effects, and they state that LLLT ameliorates mental disorders in individuals with depression, though the abstract gives no supporting numbers. The authors call for a fuller understanding of mechanisms before therapeutic use.
- Who or what was studied
- Individuals with depression, with preclinical animal models cited for neuroprotective effects
- Wavelengths
- 400, 700, 800, 1100 nm
- Limits stated in the abstract
- The abstract is a narrative review that reports no pooled sample size, study count, or quantitative results, and the mechanisms it describes are not fully established.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sbmu.ac.ir.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 400-700 nm, 800-1100 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Depression, Adenosine triphosphate, Photobiomodulation, Near-infrared, Wavelength, Inflammation, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.